NewsRoom Articles - Page 96 of 154 - PsychedelicNewsWire (PNW)

FridayJun 04, 2021 9:30 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Direct-To-Consumer Amazon Store under Pure Mushrooms Brand

PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platform Store features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021 Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026 Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently announced that Pure Mushrooms Corp., its wholly owned subsidiary, has opened a direct-to-consumer, e-Commerce store…

ThursdayJun 03, 2021 3:00 pm

Deepak Chopra Plans to Raise Awareness About Healing Potential of Psychedelics

Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his statement, the self-care leader announced that the collaboration was for the public awareness of psychedelic research and public education, adding that while he didn’t believe psychedelics were a universal cure, they had a huge role to play in suicide prevention and the treatment of depression and post-traumatic stress disorder, among other conditions. A phase 3 clinical trial conducted by MindMed…

ThursdayJun 03, 2021 10:31 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces

Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label products Company’s involvement in functional, psychoactive mushrooms space is also gaining steam Pure Extracts’ current R&D focus is on psychoactive mushroom compounds Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and partnerships. Pure Extracts’ CEO Ben Nikolaevsky recently released a corporate update focused on three main points of interest — cannabis, functional mushrooms and psilocybin — in its growing business (https://ibn.fm/0v5sO). The update noted that…

ThursdayJun 03, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin

Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials The company intends to contribute to the growing body of research through academic collaborations with leading American institutions The research will focus on indications that other pharmaceutical companies have largely ignored Although we can accurately describe the psychedelics industry as nascent, psychedelics have been the subject of a flurry of groundbreaking research that have gradually lifted the stigma surrounding…

WednesdayJun 02, 2021 1:30 pm

Peyote: The Less-Known Psychedelic with Numerous Benefits

Psychedelics such as LSD, MDMA, ayahuasca and psilocybin have become popular in the last few years as researchers discover more about the substances and the therapeutic benefits they possess. While these substances have been a part of the popular culture in the West for some decades now, other psychedelics, including peyote, have been used by Indigenous people in spiritual and healing practices for many millennia. Peyote, which is a less-popular psychedelic, is a spineless cactus that naturally grows in various parts of Mexico and Southern Texas. The cactus is small and bears the shape of a caterpillar cocoon, which explains…

WednesdayJun 02, 2021 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements

Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial The company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, Germany Pilot project involving rapid COVID-19 PCR tests has been initiated in Germany, promising efficacy and accuracy of results in as little as 25 minutes XPhyto is currently in talks and negotiations with distribution and wholesale partners, with a potential…

TuesdayJun 01, 2021 1:00 pm

California Bill to Legalize Psychedelic Possession to Be Advanced to Senate Floor

A measure to legalize the possession of psychedelic substances in the state of California may soon advance to the Senate. The bill, which was sponsored by Sen. Scott Wiener, has already been approved by two policy committees. However, it will need to be approved by the Senate Appropriations Committee so that it can be added to the Senate calendar. It was cleared by the panel in a 5-to-2 vote. The full chamber may begin debates on the reform initiative by June 4. If it is approved, the initiative will be advanced to the Assembly, and then possibly to the governor’s…

FridayMay 28, 2021 12:00 pm

Drug Developer Opts for RWE Model to Study Psychedelic Therapies

Albert Labs, a UK-based R&D company, is exploring a new way to fast track how quickly patients can access psychedelic therapies by leveraging Real World Evidence (“RWE”) while developing the medicines needed to manage a variety of mental health ailments. While the current range of pharmaceutical medicines for mental health issues is diverse, an increasing number of patients aren’t responding to these conventional treatments. Additionally, some mental health issues seem to have no current treatment modality indicated for them. A case in point is cancer-induced anxiety, which can lower treatment compliance rates and even drive up the number of suicides…

FridayMay 28, 2021 11:31 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021 Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development Bio-pharmaceutical…

ThursdayMay 27, 2021 12:30 pm

Legendary Investor Believes Investment Potential of Psychedelics Exceeds That of Marijuana

Psychedelics drugs are becoming more popular as more research discovers the potential they possess for treating various mental health conditions. These substances have been ignored since the 1960s, and while they are still illegal in various states across the country, many companies are betting that the substances will be big, given both the anecdotal and preliminary scientific evidence showing that the compounds may be even more efficacious than the current pharmaceuticals prescribed to manage various disorders. These findings have garnered the attention of many, from Wall Street to independent investors, who believe that psychedelics will be huge in the near…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000